NEWS & EVENTS

Events

SpikImm at BIO-Europe Spring

SpikImm will be represented at BIO-Europe Spring, one of the most important partnering events for the global biotechnology industry.

The event gathers biotechnology companies, investors, and industry leaders to explore partnerships and discuss the latest advances in life sciences and healthcare innovation.

Participants interested in meeting with SpikImm during the conference are invited to contact the company to arrange a discussion.

For meeting requests, please contact:
paul.gineste@spikimm.com

44th Annual J.P. Morgan Healthcare Conference January 12-15, 2026 San Francisco, Californ

News

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

SPIKIMM receives 15 Million Euros in non-dilutive funding awarded by France 2030 to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-COV-2

SPIKIMM, a biotech company founded by Truffle Capital and Institut Pasteur, announce that SPK001, its monoclonal antibody has demonstrated a potent and broad neutralization activity across all SARS-COV-2 variants of concern, including Omicron (BA.1 AND BA.2)

Coronavirus variants are dodging antibody treatments. New lab-made options may help

Long-term benefits of clean energy sources

SpikImm announces the signature of an exclusive license option and
collaboration agreement with SATT Conectus

France 2030 : la recherche et l’innovation au cœur des enjeux pour prévenir et lutter contre les maladies infectieuses émergentes et les menaces nucléaire, radiologique, biologique et chimique

SPIKIMM, a biotechnology company founded by Truffle Capital under license from the Institut Pasteur, announces that the clinical trials for SPK001, its monoclonal antibody against SARS-COV-2, have begun

‘Super-antibodies’ could curb COVID-19 and help avert future pandemics

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants